Trials / Completed
CompletedNCT02071004
DS1040b/Aspirin Drug/Drug Interaction Study
A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1, open label, single dose study, after 5 days of aspirin treatment, in healthy male and female subjects. It is hypothesized that co-administering DS-1040b with aspirin at steady state will be safe and well tolerated by healthy male and female subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DS-1040b | IV of 6 mg given once over 30 minutes |
| DRUG | Aspirin | Dispersible tablet, 300mg \& 75 mg, once daily for 5 days |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2014-02-25
- Last updated
- 2018-12-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02071004. Inclusion in this directory is not an endorsement.